MedTrace Logo

Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients

NCT05447013 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2022-11-23

No results posted yet for this study

Summary

Open-label phase I (single-center)/ phase II (multicenter) with randomization 2:1

Conditions

  • Severe COVID-19

Interventions

BIOLOGICAL

Coronavirus-2-specific T cells

Coronavirus-2-specific T cells ex vivo expanded from selected COVID-19 recovered donors

OTHER

standard of care (SOC)

standard of care (SOC)

Sponsors & Collaborators

  • General Hospital Of Thessaloniki Ippokratio

    collaborator OTHER

  • George Papanicolaou Hospital

    lead OTHER

Principal Investigators

  • Evangelia Yannaki, MD,PI · George Papanicolaou Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-02
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05447013 on ClinicalTrials.gov